Abstract
Due to the fact that an increased number of patients have experienced bloodstream infections caused by Candida species and the high mortality of this infection, there is a need for a strategy to reduce this scenery. One possible strategy is the use of new drugs, such as fructose-1,6-bisphosphate (FBP), which is a high-energy glycolytic metabolite and has shown to have therapeutic effects in several pathological conditions such as ischemia, shock, toxic injuries, and bacterial sepsis. The aim of this manuscript was to determine the role of FBP in experimental Candida albicans bloodstream infection. We used mice that were divided into three experimental groups: sham (not induced), bloodstream infection (induced with intratracheal instillation of C. albicans) and FBP (bloodstream infection plus FBP 500 mg/kg i.p.). Blood was taken for assessment of complete hematological profile and cytokine assay (IL-6 and MCP-1). Results of the study demonstrated that mortality decreased significantly in groups that received FBP. All cytokine and hematological indexes of FBP group were similar to bloodstream infection group with exception of platelets count. FBP significantly prevented the decrease in platelets. Taken together, our results demonstrate that FBP prevented the mortality in C. albicans bloodstream infection.
Similar content being viewed by others
REFERENCES
Lamagni, T.L., B.G. Evans, M. Shigematsu, and E.M. Johnson. 2001. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990–9). Epidemiology and Infection 126: 397–414.
Eloy, O., V. Blanc, P. Pina, A. Gaudart, M.L. Bressole, C. Plainvert, et al. 2006. Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004. Pathologie Biologie 54: 523–530.
Wisplinghoff, H., T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel, and M.B. Edmond. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical Infectious Diseases 39: 309–317.
Gudlaugsson, O., S. Gillespie, K. Lee, J. Vande Berg, J. Hu, S. Messer, et al. 2003. Attributable mortality of nosocomial candidemia revisited. Clinical Infectious Diseases 37: 1172–1177.
Martin, G.S., D.M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. The New England Journal of Medicine 348: 1546–1554.
Xu, K., and J.L. Stringer. 2008. Pharmacokinetics of fructose-1,6-diphosphate after intraperitoneal and oral administration to adult rats. Pharmacological Research 57: 234–238.
Yin, H., X.B. Jin, Q. Gong, H. Yang, H. Li, F.L. Gong, et al. 2008. Fructose-1,6-diphosphate attenuates acute lung injury induced by lipopolysaccharide in mice. International Immunopharmacology 20: 1842–1847.
Lopes, R.P., A. Lunardelli, T. Preissler, C.E. Leite, J.C.F. Alves-Filho, F.B. Nunes, et al. 2006. The effects of fructose-1,6-bisphosphate and dexamethasone on acute inflammation and T-cell proliferation. Inflammation Research 55: 354–358.
Nunes, F.B., J.C.F. Alves-Filho, C.M. Alves Bastos, P.M. Tessele, E. Caberlon, K.B. Moreira, et al. 2004. Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacological Research 49: 449–453.
Alves-Filho, J.C., R.C. Santos, T.A. Castaman, and J.R. Oliveira. 2004. Anti-inflammatory effects of fructose-1,6-bisphosphate on carrageenan-induced pleurisy in rat. Pharmacological Research 49: 245–248.
Nunes, F.B., M.G. Simões Pires, J.C.F. Alves-Filho, P.H. Wachter, and J.R. Oliveira. 2002. Physiopathological studies in septic rats and the use of fructose 1,6-bisphosphate as cellular protection. Critical Care Medicine 30: 2069–2074.
Nunes, F.B., C.M. Graziottin, J.C.F. Alves-Filho, P.H. Wachter, and J.R. Oliveira. 2003. An assessment of fructose-1,6-bisphosphate as an antimicrobial and anti-inflammatory agent in sepsis. Pharmacological Research 47: 35–44.
Levi, M. 2008. The coagulant response in sepsis. Clinics in Chest Medicine 29: 627–642.
Remick, D.G., G. Bolgos, S. Copeland, and J. Siddiqui. 2005. Role of interleukin-6 in mortality from and physiologic response to sepsis. Infection and Immunity 5: 2751–2757.
Nunes, F.B., P.B. Gaspareto, R.C.V. Santos, M. de Assis, C.M. Graziottin, V. Biolchi, et al. 2003. Intravenous toxicity of fructose-1,6-bisphosphate in rats. Toxicology Letters 143(1): 73–81.
Papadimitriou, J.M., and R.B. Ashman. 1986. The pathogenesis of acute systemic candidiasis in a susceptible inbred mouse strain. The Journal of Pathology 150: 257–265.
Romani, L., A. Mencacci, E. Cenci, R. Spaccapelo, P. Mosci, P. Puccetti, and F. Bistoni. 1993. CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. Journal of Immunology 150: 925–931.
Hurley, R. 1996. Effect of route of entry of Candida albicans on the histogenis of the lesions in experimental candidosis in the mouse. Journal of Pathology and Bacteriology 92: 578–583.
Nuget, K.M., and J.M. Onofrio. 1983. Pulmonary tissue resistance to Candida albicans in normal and immunosuppressed mice. American Review of Respiratory Disease 128: 909–914.
Sawyer, R.T. 1990. Experimental pulmonary candidiasis. Mycopathologia 109: 99–109.
Fallon, K., K. Bausch, J. Noonan, E. Huguenel, and P. Tamburini. 1997. Role of aspartic proteases in disseminated Candida albicans infection in mice. Infection and Immunity 65: 551–556.
de Mello, R.O., A. Lunardelli, E. Caberlon, C.M. de Moraes, R. Christ Vianna Santos, V.L. da Costa, et al. 2010. Effect of N-acetylcysteine and fructose-1,6-bisphosphate in the treatment of experimental sepsis. Inflamm. doi:10.1007/s10753-010-9261-9.
Oliveira, L.M., M.G.S. Pires, A.B. Magrisso, T.P. Munhoz, R. Roesler, and J.R. Oliveira. 2010. Fructose-1, 6-bisphosphate inhibits in vitro and ex vivo platelet aggregation induced by ADP and ameliorates coagulation alterations in experimental sepsis in rats. Journal of Thrombosis and Thrombolysis 29: 387–394.
Hechler, B., C. Léon, C. Vial, P. Vigne, C. Frelin, J.P. Cazenave, et al. 1998. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 92(1): 152–159.
Cavallini, L., R. Deana, M.A. Francesconi, and A. Alexandre. 1992. Fructose-1,6-diphosphate inhibits platelet activation. Biochemical Pharmacology 43(7): 1539–1544.
Levi, M., E. Jonge, and T. Van Der Poll. 2003. Sepsis and disseminated intravascular coagulation. Journal of Thrombosis and Thrombolysis 16(1–2): 43–47.
Biswas, P., F. Delfanti, S. Bernasconi, M. Mengozzi, M. Cota, N. Polentarutti, et al. 1998. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 91(1): 258–265.
Sola, A., J. Panes, C. Xaus, and G. Hotter. 2003. Fructose-1,6-biphosphate and nucleoside pool modifications prevent neutrophil accumulation in the reperfused intestine. Journal of Leukocyte Biology 73: 74–81.
Yin, H., X.B. Jin, Q. Gong, H. Yang, L.Y. Hu, F.L. Gong, et al. 2008. Fructose-1,6-diphosphate attenuates acute lung injury induced by lipopolysaccharide in mice. International Immunopharmacology 8(13–14): 1842–1847.
ACKNOWLEDGMENTS
This study was supported by grants from FAPERGS and CAPES/DGU (BEX 4422/09-0 and BEX3449/11-4), Brazil; Institut d’Investigació Biomèdica de Bellvitge (IDIBELL); and Secretaría de Estado de Universidades, Ministerio de Ciencia e Innovación (PHB2008-0080-PC), Spain.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Santos, R.C.V., Moresco, R.N., Peña Rico, M.A. et al. Fructose-1,6-Bisphosphate Reduces the Mortality in Candida albicans Bloodstream Infection and Prevents the Septic-Induced Platelet Decrease. Inflammation 35, 1256–1261 (2012). https://doi.org/10.1007/s10753-012-9436-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-012-9436-7